Disease · MONDO_0006804
inflammatory breast carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. inflammatory breast carcinoma. Diseases, record MONDO_0006804. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006804
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- inflammatory breast cancer, inflammatory carcinoma of breast, inflammatory carcinoma of the breast, mastitis Carcinomatosa
- Open Targets
Drugs45
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 16 | 16 | 16 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| EPIRUBICIN | CHEMBL417 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| FILGRASTIM | CHEMBL1201567 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| LAPATINIB | CHEMBL554 | Small molecule | Phase 2 | ClinicalTrials.gov and TTD | 5 | 4 | 4 | Drugs and targets |
1 to 10 of 45
See all 45 drugsTargets76
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 7 | Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 5 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 4 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 4 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 4 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 4 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 4 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| TUBA1A | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
1 to 10 of 76
See all 76 targetsTrials40
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00856492 | S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer | Phase 2 | 215 | 2017-06-27 | Breast Cancer | BEVACIZUMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, PEGFILGRASTIM | Its record names the disease | ClinicalTrials.gov |
| NCT00558103 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | Phase 2 | 163 | 2012-07-18 | Neoplasms, Breast | LAPATINIB, PAZOPANIB | Its record names the disease | ClinicalTrials.gov |
| NCT02411656 | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | Phase 2 | 71 | 2025-07-02 | Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Peau d'Orange, Progesterone Receptor Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Inflammatory Breast Carcinoma, Triple-Negative Breast Carcinoma | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01036087 | Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer | Phase 2 | 47 | 2022-09-21 | Breast Cancer | CARBOPLATIN, CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL, PACLITAXEL, PANITUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00003042 | Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer | Phase 2 | 41 | 2021-04-08 | Breast Cancer | CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, FILGRASTIM, MELPHALAN, PACLITAXEL, TAMOXIFEN CITRATE | Its record names the disease | ClinicalTrials.gov |
| NCT02971748 | Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | Phase 2 | 36 | 2026-01-22 | Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8 | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | Phase 1/2 | 34 | 2026-02-12 | Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7 | NERATINIB, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01325428 | Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer | Phase 2 | 26 | 2016-02-11 | Breast Neoplasms | AFATINIB, VINORELBINE | Its record names the disease | ClinicalTrials.gov |
| NCT01796197 | Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | Phase 2 | 23 | 2021-09-05 | Breast Cancer | PACLITAXEL, PERTUZUMAB, TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02876302 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | Phase 2 | 23 | 2024-04-18 | Inflammatory Breast Cancer (IBC) | CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL, RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 40
See all 40 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) vs Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)): Event-free Survival | 20 of 98 | 24 of 113 | 211 | NCT00856492 | Trial comparisons |
| Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) vs Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)): Number of Patients With Pathological Complete Response Rate | 35 of 98 | 24 of 113 | 211 | NCT00856492 | Trial comparisons |
| Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue vs High-dose Chemo With Rescue: deaths from any cause | 10 of 14 | 14 of 27 | 41 | NCT00003042 | Trial comparisons |
| Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue vs High-dose Chemo With Rescue: serious adverse events | 0 of 14 | 2 of 27 | 41 | NCT00003042 | Trial comparisons |
| Part A: Afatinib Once Daily (OD). vs Part B: Afatinib+V (Vinorelbine).: serious adverse events | 12 of 26 | 4 of 10 | 36 | NCT01325428 | Trial comparisons |
| Arm A: Eribulin followed by AC vs Arm B: AC followed by Eribulin: deaths from any cause | 1 of 16 | 0 of 6 | 22 | NCT02623972 | Trial comparisons |
| Arm A: Eribulin followed by AC vs Arm B: AC followed by Eribulin: serious adverse events | 5 of 16 | 1 of 6 | 22 | NCT02623972 | Trial comparisons |
| HER2-negative, Including TNBC or HR-positive vs HER2-positive, Independent of HR Status: Number of Participants Who Had a Pathological Complete Response (pCR) | 0 of 4 | 3 of 4 | 8 | NCT03742986 | Trial comparisons |
| HER2-negative, Including TNBC or HR-positive vs HER2-positive, Independent of HR Status: Number of Participants Who Had a Pathological Complete Response (pCR) | 1 of 4 | 3 of 4 | 8 | NCT03742986 | Trial comparisons |
| HER2-negative, Including TNBC or HR-positive vs HER2-positive, Independent of HR Status: deaths from any cause | 0 of 4 | 0 of 4 | 8 | NCT03742986 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials20
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006804
GET https://conductscience.org/api/diseases/v1/MONDO_0006804/drugs?page=2